期刊
SUPPORTIVE CARE IN CANCER
卷 24, 期 3, 页码 1439-1447出版社
SPRINGER
DOI: 10.1007/s00520-015-3063-4
关键词
Chemotherapy; Peripheral neuropathy; Cancer; Clinical trials
资金
- NCI NIH HHS [U10 CA180802] Funding Source: Medline
- NINR NIH HHS [R01 NR015259] Funding Source: Medline
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common and debilitating complications of cancer treatment. Due to a lack of effective management options for patients with CIPN, the National Cancer Institute (NCI) sponsored a series of trials aimed at both prevention and treatment. A total of 15 such studies were approved, evaluating use of various neuro-modulatory agents which have shown benefit in other neuropathic pain states. Aside from duloxetine, none of the pharmacologic methods demonstrated therapeutic benefit for patients with CIPN. Despite these disappointing results, the series of trials revealed important lessons that have informed subsequent work. Some examples of this include the use of patient-reported symptom metrics, the elimination of traditional-yet unsubstantiated-practice approaches, and the discovery of molecular genetic predictors of neuropathy. Current inquiry is being guided by the results from these large-scale trials, and as such, stands better chance of identifying durable solutions for this treatment-limiting toxicity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据